source
- J&J's Talvey plus Darzalex Faspro cuts death risk by up to 53% in relapsed multiple myelomaJohnson & Johnson reported that a combination of its immunotherapy Talvey with Darzalex Faspro, with or without Pomalyst, significantly lowered the risk of death in patients with relapsed or refrac…
- Lilly reports early positive results for new JAK2 inhibitor in hard-to-treat myelofibrosisLilly has incorporated a JAK2‑targeting drug originally discovered by Ajax Therapeutics after its recent acquisition. The experimental pill is intended for patients with myelofibrosis, a difficult‑…